| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Impurity of Mycophenolate mofetil
Methyl mycophenolate targets inosine monophosphate dehydrogenase (IMPDH), the same target as mycophenolic acid. IMPDH is a key enzyme in the de novo synthesis of guanine nucleotides, which is essential for lymphocyte proliferation. By inhibiting IMPDH, methyl mycophenolate (as a prodrug of MPA) suppresses T- and B-lymphocyte proliferation, exerting immunosuppressive effects. This makes it useful in the prevention of organ transplant rejection and treatment of autoimmune diseases. |
|---|---|
| ln Vitro |
In vitro, methyl mycophenolate is a prodrug of mycophenolic acid (MPA) and an impurity of Mycophenolate mofetil. As an IMPDH inhibitor, it suppresses lymphocyte proliferation. Its activity is typically evaluated using lymphocyte proliferation assays and IMPDH enzyme activity assays. However, specific IC50 values for methyl mycophenolate itself are not detailed in the available literature, as it is primarily a prodrug and impurity standard.
|
| ln Vivo |
In vivo, methyl mycophenolate is a prodrug of mycophenolic acid (MPA). After administration, it is hydrolyzed to MPA, the active immunosuppressive agent. MPA is used in organ transplantation to prevent rejection and in autoimmune disease treatment. As a prodrug and impurity, methyl mycophenolate is not administered directly for therapeutic purposes. Its in vivo effects are primarily studied in the context of MPA pharmacokinetics and metabolism.
|
| Enzyme Assay |
Cell-free assays for methyl mycophenolate typically involve analytical characterization rather than biological activity measurements. The compound is used as a reference standard for the analysis of mycophenolate mofetil and its impurities. Its identity and purity are confirmed by HPLC, NMR, and mass spectrometry. IMPDH inhibition assays could be performed using purified IMPDH enzyme, but specific protocols for this compound are not detailed in the available literature.
|
| Cell Assay |
In vitro cellular assays for methyl mycophenolate are not typically performed, as the compound is primarily used as a reference standard and prodrug. If studied, lymphocyte proliferation assays would be used to assess immunosuppressive activity. Cells would be treated with various concentrations of methyl mycophenolate, and proliferation would be measured by [3H]-thymidine incorporation or similar methods. However, specific assay protocols for this compound are not documented in the available literature.
|
| Animal Protocol |
In vivo animal studies for methyl mycophenolate are not typically conducted, as the compound is primarily used as a reference standard and prodrug. Studies on mycophenolic acid and its prodrugs are conducted in models of transplantation and autoimmune disease. The compound is administered orally or intravenously, and immunosuppressive efficacy is assessed. However, specific data for methyl mycophenolate are not extensively reported in the available literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of methyl mycophenolate include a molecular weight of 334.36 g/mol and molecular formula C18H22O6. As a prodrug of mycophenolic acid, it is hydrolyzed to MPA in vivo. The compound is typically stored at appropriate conditions as a reference standard. Detailed ADME parameters such as half-life, Cmax, and AUC are not extensively reported in the available literature for methyl mycophenolate itself, as it is primarily a prodrug and impurity.
|
| Toxicity/Toxicokinetics |
The toxicity profile of methyl mycophenolate is related to its hydrolysis product, mycophenolic acid. MPA has well-characterized toxicities including gastrointestinal effects, hematological effects (leukopenia, anemia), and increased risk of infections. The compound is intended for research and analytical use only and not for therapeutic applications. Standard safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Investigation of the marine fungus Phaeosphaeria spartinae have isolated a new enantiomer of trioctanoic acid, namely (-)-trioctanoic acid (1), a new polyketide compound Spatino E (2), and three known compounds (3-5). Keywords: 8-hydroxy-6-methoxy-3-methylisocoumarin; Phaeosphaeria spartinae; hyperoyl alcohol; marine natural products; methyl mycophenolic acid; Spatino E. [1]
Methyl mycophenolate is the methyl ester of mycophenolic acid (MPA), an impurity of Mycophenolate mofetil, and a prodrug of MPA. It has potent immunosuppressive activity. Its molecular formula is C18H22O6 with a molecular weight of 334.36 g/mol. Methyl mycophenolate is used as a reference standard in pharmaceutical quality control and analytical method development. It is not for therapeutic use. |
| Molecular Formula |
C18H22O6
|
|---|---|
| Molecular Weight |
334.36368
|
| Exact Mass |
334.142
|
| Elemental Analysis |
C, 64.66; H, 6.63; O, 28.71
|
| CAS # |
31858-66-9
|
| Related CAS # |
(E/Z)-Methyl mycophenolate;24243-40-1
|
| PubChem CID |
6478685
|
| Appearance |
White to off-white solid powder
|
| Density |
1.222g/cm3
|
| Boiling Point |
540.4ºC at 760 mmHg
|
| Melting Point |
105-106ºC
|
| Flash Point |
194.1ºC
|
| Index of Refraction |
1.556
|
| LogP |
2.821
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
24
|
| Complexity |
500
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OC)O
|
| InChi Key |
ZPXRQFLATDNYSS-BJMVGYQFSA-N
|
| InChi Code |
InChI=1S/C18H22O6/c1-10(6-8-14(19)22-3)5-7-12-16(20)15-13(9-24-18(15)21)11(2)17(12)23-4/h5,20H,6-9H2,1-4H3/b10-5+
|
| Chemical Name |
methyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
|
| Synonyms |
Methyl mycophenolate; 31858-66-9; Methyl Mycophenolate (EP Impurity E); Mycophenolic Acid Methyl Ester; (E/Z)-Methyl mycophenolate; 24243-40-1; methyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate; 0B5C0EG8E8;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~299.08 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.48 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.48 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.48 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9908 mL | 14.9539 mL | 29.9079 mL | |
| 5 mM | 0.5982 mL | 2.9908 mL | 5.9816 mL | |
| 10 mM | 0.2991 mL | 1.4954 mL | 2.9908 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
